E-MTAB-5462
RNAseq analysis of human peritoneal dialysis effluent cells treated with or without alanyl-glutamine supplemented peritoneal dialysis fluid in a randomized controlled cross-over pilot study
The impact of PDF supplementation with alanyl-glutamine (AlaGln) on peritoneal immune-competence in 6 patients in an open-label, randomized, crossover pilot trial (EudraCT 2012-004004-36) was tested by relating functional test results to transcriptome changes (RNAseq and miRNA analysis) in PD effluent cells.
The impact of PDF supplementation with alanyl-glutamine (AlaGln) on peritoneal immune-competence in 6 patients in an open-label, randomized, crossover pilot trial (EudraCT 2012-004004-36) was tested by relating functional test results to transcriptome changes (RNAseq and miRNA analysis) in PD effluent cells.